CLDN18 and gastric cancer: In addition, on the basis of the overexpression of CLDN18.2 (Dottermusch et al., 2019; Nakayama et al., 2024; Sahin et al., 2008) and RTKs (Katoh et al., 2024a; Lee et al., 2012; Van Cutsem et al., 2015) in human gastric cancers, it was previously predicted that bispecific ADCs, such as CLDN18.2 x FGFR2 (fibroblast growth factor receptor 2), CLDN18.2 x HER2 and CLDN18.2 x MET, would be developed for the treatment of minor subsets of gastric cancer patients in the future (Katoh and Katoh, 2024).